Vnitr Lek 2022, 68(7):444-448 | DOI: 10.36290/vnl.2022.093

Covid-19 in kidney transplant recipients

Mária Magicová, Ondřej Viklický
Klinika nefrologie, Transplantační centrum, Institut klinické a experimentální medicíny, Praha

Kidney transplant recipients are a very vulnerable population at risk of severe course and death from Covid-19. Several antiviral drugs are now available for the treatment of nonhospitalized individuals with mild to moderate Covid-19 and hospitalized patients with severe disease. The combination of monoclonal antibodies is also available to be used as pre-exposure prophylaxis in elderly patients. Previously used monoclonal antibodies for post-exposure prophylaxis are no longer effective because of the new mutations and are no longer recommended. Although the immune response to Covid-19 vaccines is impaired in kidney transplant recipients, the effectiveness of the Covid-19 vaccines was described even in this immunocompromised group. Therefore vaccination, together with anti-epidemic measures, remains the most important tool to prevent Covid-19.

Keywords: antiviral drugs, Covid-19, vaccine effectiveness, monoclonal antibodies, mRNA vaccine, vaccination, pre‑exposure prophylaxis, SARS‑CoV-2, kidney transplantation, vector vaccine.

Accepted: October 17, 2022; Published: October 31, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Magicová M, Viklický O. Covid-19 in kidney transplant recipients. Vnitr Lek. 2022;68(7):444-448. doi: 10.36290/vnl.2022.093.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Information on COVID-19 Treatment, Prevention and Research. COVID-19 Treatment Guidelines. [cited June 2022]. Avalible from: https://www.covid19treatmentguidelines.nih.gov/
    2. Gottlieb RL, Vaca CE, Paredes R et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305-315. Go to original source... Go to PubMed...
    3. Ackley TW, McManus D, Topal JE, Cicali B, Shah S. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. Antimicrob Agents Chemother. 2021;65(2):e02290-20. Go to original source... Go to PubMed...
    4. Jayk Bernal A, Gomes da Silva MM, Musungaie DB et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-520. Go to original source... Go to PubMed...
    5. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. N Engl J Med. 2022;386(10):995-998. Go to original source... Go to PubMed...
    6. Hammond J, Leister‑Tebbe H, Gardner A et al. Oral Nirmatrelvir for High‑Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542. Go to original source... Go to PubMed...
    7. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-1826. Go to original source... Go to PubMed...
    8. RECOVERY Collaborative Group, Horby P, Lim WS et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. Go to original source... Go to PubMed...
    9. Prendecki M, Clarke C, Gleeson S et al. Detection of SARS‑CoV-2 Antibodies in Kidney Transplant Recipients. J Am Soc Nephrol. 2020;31(12):2753-2756. Go to original source... Go to PubMed...
    10. Magicova M, Fialova M, Zahradka I et al. Humoral response to SARS‑CoV-2 is well preserved and symptom dependent in kidney transplant recipients. Am J Transplant. 2021;21(12):3926-3935. Go to original source... Go to PubMed...
    11. Bertrand D, Hamzaoui M, Drouot L et al. SARS‑CoV-2-specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. Transplant Direct. 2021;7(12):e792. Go to original source... Go to PubMed...
    12. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS‑CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021;325(21):2204-2206. Go to original source... Go to PubMed...
    13. Magicova M, Zahradka I, Fialova M et al. Determinants of Immune Response to Anti‑SARS‑CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation. 2022;106(4):842-852. Go to original source... Go to PubMed...
    14. Chavarot N, Ouedrani A, Marion O et al. Poor Anti‑SARS‑CoV-2 Humoral and T‑cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation. 2021;105(9):e94-e95. Go to original source... Go to PubMed...
    15. Li P, Wang Y, Lavrijsen M et al. SARS‑CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32(3):322-324. Go to original source... Go to PubMed...
    16. Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect, DiS. 2021;23(5):e13705. Go to original source... Go to PubMed...
    17. Zahradka I, Petr V, Modos I, Magicova M, Dusek L, Viklicky O. Association Between SARS‑CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients : A Registry‑Based Report [published online ahead of print, 2022 May 3]. Ann Intern Med. 2022;M21-2973. Go to original source... Go to PubMed...
    18. Callaghan CJ, Mumford L, Curtis RMK et al. Real‑world Effectiveness of the Pfizer‑BioNTech BNT162b2 and Oxford‑AstraZeneca ChAdOx1-S Vaccines Against SARS‑CoV-2 in Solid Organ and Islet Transplant Recipients. Transplantation. 2022;106(3):436-446. Go to original source... Go to PubMed...
    19. Bruxvoort KJ, Sy LS, Qian L et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS‑CoV-2: test negative case‑control study. BMJ. 2021;375:e068848. Published 2021 Dec 15. Go to original source... Go to PubMed...
    20. Andrews N, Stowe J, Kirsebom F et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1. 1. 529) Variant. N Engl J Med. 2022;386(16):1532-1546. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.